Mouse Monoclonal Antibody to GAPDH (Clone : 3B1E9)(Discontinued)
|Amount :||100 µg|
|Isotype :||Mouse IgG2a, κ|
|Purification :||Protein A chromatography|
|Content :||0.5 mg/ml, lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.|
|Storage condition :||The antibody is stable in lyophilized form if stored at -20°C or below. The reconstituted antibody can be stored for 2-3 weeks at 2-8°C. For long term storage, aliquot and store at -20°C or below. Avoid repeated freezing and thawing cycles.|
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is well known as one of the key enzymes involved in glycolysis. It catalyzes an important energy-yielding step in carbohydrate metabolism, the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate in the presence of inorganic phosphate and nicotinamide adenine dinucleotide (NAD). The enzyme exists as a tetramer of identical chains. Besides its functioning as a glycolytic enzyme in cytoplasm, recent evidence suggest that mammalian GAPDH is also involved in a great number of intracellular proceses such as membrane fusion, microtubule bundling, phosphotransferase activity, nuclear RNA export, DNA replication, and DNA repair. During the last decade a lot of findings appeared concerning the role of GAPDH in different pathologies including prostate cancer progression, programmed neuronal cell death, age-related neuronal diseases, such as Alzheimers and Huntingtons disease. GAPDH Antibody, mAb, Mouse is produced from the hybridoma resulting from fusion of Sp2/0 myeloma and lymphocytes obtained from mouse immunized with human GAPDH protein from erythrocytes.
ELISA: 0.05-0.2 µg/ml
Western blot: 1-2 µg/ml
Reconstitute the lyophilized powder with deionized water (or equivalent) to an antibody concentration of 0.5 mg/ml.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|Subcellular location:||Cytoplasm, Nucleus, Cytoplasm, Membrane, Cytoplasm|
|Post transnational modification:||Oxidative stress can promote the formation of high molecular weight disulfide-linked GAPDH aggregates, through a process called nucleocytoplasmic coagulation. Such aggregates can be observed in vivo in the affected tissues of patients with Alzheimer disease or alcoholic liver cirrhosis, or in cell cultures during necrosis. Oxidation at Met-46 may play a pivotal role in the formation of these insoluble structures. This modification has been detected in vitro following treatment with free radical donor (+/-)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide. It has been proposed to destabilize nearby residues, increasing the likelihood of secondary oxidative damages, including oxidation of Tyr-45 and Met-105. This cascade of oxidations may augment GAPDH misfolding, leading to intermolecular disulfide cross-linking and aggregation.|
|BioGrid:||108868. 233 interactions.|